Will ADMA disclose an SEC formal investigation by year-end 2026?

SEC formal investigations following short seller reports are relatively uncommon. The Culper Research report was published roughly a year ago and no SEC disclosure has appeared. KPMG (Big 4) issued an unqualified audit opinion on FY2025, which provides institutional validation. CEO buying during the decline is atypical for fraud. The law firm investigations are plaintiff attorney ambulance-chasing, not SEC action. However, the specific AR/DSO concerns have some substance, and the SEC does investigate channel stuffing allegations. Low probability but non-trivial.

SEC investigations are opaque and the absence of disclosure does not mean absence of inquiry. Preliminary inquiries do not require disclosure. However, the question specifically asks about a formal investigation disclosure (Wells notice, subpoena), which would be a material event. The base rate for short seller reports leading to SEC formal investigations is roughly 10-20%. ADMA specific circumstances (some legitimate AR concerns, but also strong product evidence and CEO buying) place it in the middle of that range. The auditor change to KPMG could either reflect proactive governance or a response to coming scrutiny.

The strongest evidence against an SEC investigation materializing is the time elapsed. Short seller reports that lead to SEC action typically see early-stage activity within 6-12 months. Nearly a year has passed with no disclosure. KPMG willingness to take on the audit engagement is a meaningful signal -- Big 4 firms conduct extensive due diligence before accepting new clients, especially controversial ones. KPMG accepting suggests they found no red flags during their onboarding review. CEO accumulation during decline further reduces probability of underlying fraud that would attract SEC attention.

SEC enforcement is unpredictable and investigations can emerge at any time. The Culper Research allegations about channel stuffing and undisclosed related-party sales are the type of claims the SEC does investigate. Multiple law firm investigations create a paper trail that the SEC can follow. However, the lack of any disclosure after nearly a year is a positive signal. The KPMG audit is a strong institutional signal. The market asks about year-end 2026, which gives another 9 months -- some probability of latent investigation materializing. 20% accounts for the residual risk.

The base rate favors NO as most short seller reports do not result in formal SEC investigations. ADMA case has some factors that could attract SEC attention (AR concentration, short seller allegations, securities litigation), but also strong counter-factors (KPMG audit, CEO buying, clinical data supporting product). The time elapsed without disclosure is increasingly reassuring. No whistleblower complaints have surfaced publicly. The new CFO hire focused on working capital suggests management is addressing the concern proactively, which is not the behavior of a company hiding fraud.

I weigh the KPMG audit heavily as Big 4 firms have enormous reputational risk from association with fraud. Their willingness to accept the engagement after due diligence is a strong institutional signal. The SEC enforcement priorities include revenue recognition and channel stuffing, but they typically act faster on clear-cut cases. The nuanced nature of ADMA situation (legitimate product, questionable AR timing) makes it less likely to attract SEC action than outright fabrication. Low probability but worth accounting for given 9-month window.

Nearly a year since short report with no SEC disclosure. KPMG Big 4 audit provides validation. CEO buying is counter-signal to fraud. But channel stuffing allegations are the type SEC does pursue, and 9 months remain in window. Low probability.

The strongest evidence is the elapsed time without disclosure. SEC investigations that will materialize typically show signs within 12 months. Management is proactively addressing concerns (new CFO, McKesson). KPMG accepted the engagement. CEO is buying. These signals collectively suggest low probability.

Base rate of short reports leading to SEC formal investigations is 10-20%. ADMA specific case has mitigating factors (KPMG, CEO buying, elapsed time) that push toward the lower end. But the allegations are specific and testable, maintaining some residual risk. 9 months remaining adds uncertainty. Low overall probability.